Notably, even in BRCA1 and BRCA2 gene mutation carriers, subsequent somatic genetic events must occur to transform a normal cell into a cancer cell (15) that can also result in therapeutic vulnerabilities. This evidence concerns the gene BRCA1 and cancer.